Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Table 1

Descriptive characteristics of the study population, means ± SD, median [IQR], or N (%).

Characteristic	Ibrutinib plus obinutuzumab
N	32
Age (years)	66 [59–73]
65 years or older (%)	17 (53)
Male	18 (56)
Cumulative illness rating scale
Total score	9 [6–11]
Greater than 6 (%)	23 (72)
ECOG performance status
0	16 (50)
1	10 (31)
2	6 (19)
Calculated creatinine clearance
Below 60 mL/min	9 (28)
Rai stage
0–II	18 (56)
III-IV	14 (44)
Lymph nodes
Median SPD, cm^2 (min-max)	17 (7–361)
Bulky disease ≥5 cm	6 (19)
Cytogenetics
Del13q	19 (59)
Trisomy 12	9 (28)
Del11q	6 (19)
Del17p	2 (6)
Unmutated IgVH	11/18 (61)
High ZAP-70 expression	10/28 (36)
Hematological parameters
Hemoglobin, g/dL	12 ± 2
Platelets × 10^9/L	147 ± 66
Neutrophils × 10^9/L	4 [3–5]
Lymphocytes × 10^9/L	59 [21–105]